Areteia Therapeutics

Areteia Therapeutics is a clinical-stage biopharmaceutical company focused on enabling better disease control and regaining control of life for patients with asthma, offering the first potential oral therapy for eosinophilic asthma. Areteia’s lead candidate is dexpramipexole, a first-in-class oral inhibitor of eosinophil maturation.